| Thursday, April 20, 2023 Image: Model of the H1ssF nanoparticle. Scientists at NIAID's Vaccine Research Center (VRC) report in two new studies that an experimental influenza vaccine, designed to protect against a broad range of influenza viruses, performed well in a small trial of volunteers. In fact, the vaccine has advanced to a second trial led by scientists at Duke University through NIAID's Collaborative Influenza Vaccine Innovation Centers (CIVICs). The Phase 1 clinical trial involved 52 volunteers and the H1ssF vaccine, which stands for influenza H1 hemagglutinin stabilized stem ferritin nanoparticle vaccine. H1ssF was safe, well-tolerated, and induced broad antibody responses that target the hemagglutinin stem. The two new studies assessing the nanoparticle vaccine published April 19 in Science Translational Medicine. Trial participants did not experience any severe adverse events; the most common vaccine reactions included mild headache, tenderness at the vaccine site, and temporary general discomfort. H1ssF generated binding antibodies to the stem of the influenza H1 hemagglutinin protein. Antibody responses were observed regardless of dose or participant age, and neutralizing antibodies were observed more than a year after vaccination.  | 
No comments:
Post a Comment